AGPAT2 Antibody
-
中文名稱：AGPAT2兔多克隆抗體
-
貨號(hào)：CSB-PA101475
-
規(guī)格：￥1100
-
圖片：
-
Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal liver cancer tissue, Primary antibody: CSB-PA101475(AGPAT2 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds
-
-
其他：
產(chǎn)品詳情
-
Uniprot No.：
-
基因名：
-
別名：AGPAT2; 1-acyl-sn-glycerol-3-phosphate acyltransferase beta; 1-acylglycerol-3-phosphate O-acyltransferase 2; 1-AGP acyltransferase 2; 1-AGPAT 2; Lysophosphatidic acid acyltransferase beta; LPAAT-beta
-
宿主：Rabbit
-
反應(yīng)種屬：Human
-
免疫原：Synthetic peptide of Human AGPAT2
-
免疫原種屬：Homo sapiens (Human)
-
標(biāo)記方式：Non-conjugated
-
抗體亞型：IgG
-
純化方式：Antigen affinity purification
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
-
產(chǎn)品提供形式：Liquid
-
應(yīng)用范圍：ELISA,WB
-
推薦稀釋比：
Application Recommended Dilution ELISA 1:2000-1:5000 WB 1:500-1:2000 -
Protocols：
-
儲(chǔ)存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能：Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone.
-
基因功能參考文獻(xiàn)：
- The findings demonstrate that AGPAT2, which is mutated in patients with congenital generalized lipodystrophy and over-expressed in different types of cancer, is a direct transcriptional target of HIF-1, suggesting that upregulation of lipid storage by HIF-1 plays an important role in adaptation and survival of cancer cells under low oxygen conditions. PMID: 29908837
- Results show that LPAATbeta had high expression in osteosarcoma patients who received cisplatin treatment and cisplatin-resistant cancer cell lines. In vitro and in vivo studies provide evidence that LPAATB plays an important role in osteosarcoma. PMID: 28035350
- Data show that missense mutation c.299G>A changes serine in the acyltransferase NHX4D motif of AGPAT2, and intronic c.493-1G>C mutation destroy a splicing site that leads to exon 4 skipping and deletion of whole AGPAT2 substrate binding domain. PMID: 24498038
- the ability of LPAAT-beta to regulate mTOR function PMID: 24205284
- miR-24 may play an important role in inhibiting osteosarcoma growth through suppression of LPAATbeta. PMID: 23578572
- novel nonsense a missense mutations were found in two patients with congenital generalized lipodystrophy type 1. PMID: 22902344
- Data suggest that AGPAT2 regulates adipogenesis through modulation of lipid metabolism/signal transduction, altering normal activation of phosphatidylinositol 3-kinase (PI3K)/protooncogene c-Akt and PPARgamma signaling in early stage of adipogenesis. PMID: 22872237
- the role of AGPAT1 or AGPAT2 in liver lipogenesis is minimal and that accumulation of liver fat is primarily a consequence of insulin resistance PMID: 21873652
- lpaat beta gene overexpression exists in both AML and CML patients. lpaat beta produced by AML cells probably plays an important role in abnormal proliferation and drug-resistance of AML cells. PMID: 21176343
- Lysophosphatidic acid acyltransferase beta (LPAATbeta) promotes the tumor growth of human osteosarcoma PMID: 21152068
- AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. PMID: 11967537
- Congenital lipodystrophy patients with Seipin mutations have a more severe lack of body fat, which affects both metabolically active and mechanical adipose tissue, compared with patients with mutations in the AGPAT2 gene. PMID: 14602785
- mutations in AGPAT2 and Gng3lg are approximately equally represented in congenital generalized lipodystrophy PMID: 15181077
- reduction in AGPAT2 enzymatic activity underlies the loss of adipose tissue in congenital generalized lipodystrophy PMID: 15629135
- Our study shows that LPAAT-beta is upregulated in ovarian cancer and is more prevalent in poorly differentiated tumours PMID: 15841084
- mutations in AGPAT2 or Seipin may have roles in Berardinelli-Seip congenital lipodystrophy PMID: 16435205
- Berardinelli-Seip syndrome is a congenital form of generalized lipodystrophy, transmitted as an autosomal recessive trait. It is well documented in medicine and skin. It is a rare disorder caused by mutations of AGPAT2 gene or BSCL2 gene. PMID: 18155601
- A new subtype of congenital generalized lipodystrophy is not associated with the AGPAT2 gene. PMID: 18698612
- We have demonstrated four novel mutations of the BSCL2 and AGPAT2 genes responsible for Berardinelli-Seip syndrome and Brunzell syndrome (AGPAT2-related syndrome). PMID: 19226263
- Study showed that the cellular level of lysophosphatidic acid was increased in AGPAT2 deficient cells. PMID: 19278620
顯示更多
收起更多
-
相關(guān)疾病：Congenital generalized lipodystrophy 1 (CGL1)
-
亞細(xì)胞定位：Endoplasmic reticulum membrane; Multi-pass membrane protein.
-
蛋白家族：1-acyl-sn-glycerol-3-phosphate acyltransferase family
-
組織特異性：Expressed predominantly in adipose tissue, pancreas and liver.
-
數(shù)據(jù)庫(kù)鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
